Progestins versus GnRH analogues for pituitary suppression during ovarian stimulation for assisted reproductive technology: a systematic review and meta-analysis
- PMID: 32327297
- DOI: 10.1016/j.rbmo.2020.01.027
Progestins versus GnRH analogues for pituitary suppression during ovarian stimulation for assisted reproductive technology: a systematic review and meta-analysis
Abstract
This systematic review and meta-analysis of comparative studies investigated whether progestins are as effective as gonadotrophin releasing hormone (GnRH) analogues for pituitary suppression in assisted reproduction. The primary outcome was live birth rate per woman. Secondary outcomes were live birth or ongoing pregnancy per woman and per embryo transfer, ongoing pregnancy, clinical pregnancy, numbers of oocytes and metaphase-two oocytes, duration of stimulation and gonadotrophin consumption. Adverse events included miscarriage, ectopic pregnancy and multiple pregnancy rates. The GRADE system was used to assess the quality of evidence. Seven studies involving a total of 2047 women were included. Three studies compared a progestin with a GnRH antagonist and four studies compared a progestin with a GnRH agonist. Most studies are non-randomized and report outcomes per embryo transfer, rather than per woman. Although progestins were similar to GnRH antagonists in effectiveness and safety parameters, they were associated with significantly higher live birth or ongoing pregnancy per embryo transfer compared with the short GnRH agonist protocol (RR 1.49, 95% CI 1.16 to 1.91). Progestin primed stimulation lasted significantly longer (mean difference 0.61 days, 95% CI 0.33 to 0.89) and required significantly more gonadotrophins (mean difference 433.2 IU, 95% CI 311.11 to 555.19) than the short GnRH agonist protocol, but the differences were clinically negligible. Safety parameters were similar between progestins and GnRH agonists. In conclusion, progestins can effectively prevent premature ovulation in assisted reproductive technology cycles. If larger and well-designed studies confirm these findings, progestins may be an effective and low-cost alternative to GnRH analogues when a fresh embryo transfer is not planned owing to a medical indication.
Keywords: Assisted reproduction; GnRH analogue; Ovarian stimulation; Progestin; ��n vitro fertilization.
Copyright © 2020 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses.Hum Reprod Update. 2021 Jan 4;27(1):48-66. doi: 10.1093/humupd/dmaa040. Hum Reprod Update. 2021. PMID: 33016316
-
Role and effectiveness of progestins in pituitary suppression during ovarian stimulation for assisted reproductive technology: a systematic review and a meta-analysis.Minerva Obstet Gynecol. 2023 Dec;75(6):573-582. doi: 10.23736/S2724-606X.22.05176-4. Epub 2022 Oct 4. Minerva Obstet Gynecol. 2023. PMID: 36193835
-
Gonadotrophin-releasing hormone antagonists for assisted conception.Cochrane Database Syst Rev. 2001;(4):CD001750. doi: 10.1002/14651858.CD001750. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001750. doi: 10.1002/14651858.CD001750.pub2. PMID: 11687120 Updated. Review.
-
Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.Curr Med Sci. 2019 Jun;39(3):431-436. doi: 10.1007/s11596-019-2055-x. Epub 2019 Jun 17. Curr Med Sci. 2019. PMID: 31209815
-
Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction.Cochrane Database Syst Rev. 2011 Aug 10;(8):CD006919. doi: 10.1002/14651858.CD006919.pub3. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2015 Nov 09;(11):CD006919. doi: 10.1002/14651858.CD006919.pub4. PMID: 21833958 Updated. Review.
Cited by
-
Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle.Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD013827. doi: 10.1002/14651858.CD013827.pub2. Cochrane Database Syst Rev. 2023. PMID: 38032057 Free PMC article. Review.
-
Progestin-primed ovarian stimulation for fertility preservation in women with cancer: A comparative study.PLoS One. 2023 Mar 28;18(3):e0280238. doi: 10.1371/journal.pone.0280238. eCollection 2023. PLoS One. 2023. PMID: 36976781 Free PMC article.
-
Implications of Progestin-Primed Ovarian Stimulation (PPOS) in a Patient With Diminished Ovarian Reserve (DOR) and Its In Vitro Fertilization (IVF) Outcome.Cureus. 2024 Feb 23;16(2):e54743. doi: 10.7759/cureus.54743. eCollection 2024 Feb. Cureus. 2024. PMID: 38523966 Free PMC article.
-
Switching from cetrorelix to dydrogesterone in an IVF cycle - a new strategy for unexpected freeze-all cycles.JBRA Assist Reprod. 2023 Oct 18;27(4):754-7. doi: 10.5935/1518-0557.20230036. Online ahead of print. JBRA Assist Reprod. 2023. PMID: 37850848 Free PMC article.
-
The clinical value of progestin-primed ovarian stimulation protocol for women with diminished ovarian reserve undergoing IVF/ICSI: a systematic review and meta-analysis.Front Endocrinol (Lausanne). 2023 Aug 21;14:1232935. doi: 10.3389/fendo.2023.1232935. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37670890 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources